Amendment No. 1 to the Research Collaboration Agreement of September 17, 2018 by and between ViaCyte, Inc. and CRISPR Therapeutics AG

AutoNDA by SimpleDocs
Time is Money Join Law Insider Premium to draft better contracts faster.